Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Taizhou Hanzhong Biopharma
Taizhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Taizhou Hanzhong Biopharma is an active Chinese biopharmaceutical company focused on oncology therapeutics. Its lead asset is pucotenlimab—a PD‑1 monoclonal antibody—which has reached Phase 3 development and received approval in China for certain indications. The company participates in the development of innovative biologics including monoclonal antibodies and oncolytic viruses through collaborations with partners such as Lepu Biopharma. It operates GMP-compliant manufacturing facilities supporting both clinical supply and commercial production.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyOncolytic virus therapyAntibody-drug conjugate
- Industry
- Biotech
02
Partnerships
Lepu Biopharma Co., Ltd.AkesoHanX Biopharma
Beyond the preview
Go deeper on Taizhou Hanzhong Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taizhou Hanzhong Biopharma.